Ocugen (NASDAQ:OCGN) Trading 12.4% Higher - Time to Buy?
Ocugen (NASDAQ:OCGN) Trading Up 12.4% - What's Next...
MarketBeat·13d ago
More News
Ocugen (OCGN) Stock Tumbles After $22.5 Million Share Offering
Ocugen shares sank sharply Wednesday after the biotech company announces a $22.5 million underwritten offering of common stock.read more...
Benzinga·14d ago
Ocugen's (OCGN) "Buy" Rating Reiterated at Chardan Capital
Chardan Capital reissued a "buy" rating and set a $7.00 price objective on shares of Ocugen in a report on Tuesday...
MarketBeat·15d ago
Ocugen, Inc. (NASDAQ:OCGN) Short Interest Update
Ocugen, Inc. (NASDAQ:OCGN - Get Free Report) was the target of a large decline in short interest in December. As of December 31st, there was short interest totaling 46,392,427 shares, a decline of...
MarketBeat·17d ago
Ocugen Stock Is Surging Today: What's Driving The Action?
Ocugen Inc (NASDAQ:OCGN) shares are up on Friday as the company is gaining traction following positive market sentiment.read more...
Benzinga·19d ago
Ocugen's Early Gene Therapy Data Shows 46% Drop In Vision Damage
Ocugen reports early phase 2 data showing its eye gene therapy reduced lesion growth by up to 54%, with no serious safety issues.read more...
Benzinga·20d ago
Novavax (NVAX) Moves 11.9% Higher: Will This Strength Last?
Novavax (NVAX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Zacks·21d ago
Ocugen (NASDAQ:OCGN) Shares Up 9% - Time to Buy?
Ocugen (NASDAQ:OCGN) Trading 9% Higher - Should You Buy...
MarketBeat·23d ago
OCGN Stock Rises Pre-Market After Gene Therapy Data Shows Promise In Rare Eye Disorder
Stargardt disease is a form of inherited macular degeneration, affecting more than 100,000 people in the U.S. and Europe combined.
Stocktwits·23d ago
Ocugen Stock Surges 75% Year to Date: What's in Store for 2026?
Ocugen rises 75% YTD as it advances three gene therapies, with multiple phase II/III readouts and filings lined up for 2026.